MAPT and Atrophy: Our analyses suggested that rates of cognitive progression were loosely coupled or even not associated with changes in markers presumed to be upstream events (i.e., changes in CSF Aβ42 and tau proteins) while were relatively more coupled with changes in markers presumed to indicate neurodegeneration and neuronal injury (i.e., ventricular enlargement, hippocampal atrophy, and brain hypometabolism).